Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- R&D Management Company More Efficient Than Council: Eisai
July 10, 2006
- Pfizer to Sell CHC Business to J&J for US$16.6 Bil.
July 10, 2006
- Eisai Licenses SERM to Radius
July 10, 2006
- OTC Version of Teijin's Aftach Recommended for Approval
July 10, 2006
- Takeda Ordered to Pay \57 Bil. in Additional Taxes
July 10, 2006
- SELF-MEDICATION NEWS IN BRIEF
July 10, 2006
- Shareholders Express Concern over Future Strategies
July 10, 2006
- R&D NEWS IN BRIEF
July 10, 2006
- BUSINESS NEWS IN BRIEF
July 10, 2006
- Highlights of 42nd ASCO Meeting Announced by Matson Jack
July 10, 2006
- NEW PRODUCTS
July 10, 2006
- New Clinical Study on Pancreatic Cancer Planned: JACCRO
July 10, 2006
- Differences between Original Drugs and Generics Do Not Mean Problems with Generics: Prof. Ogata
July 10, 2006
- BI"Sifrol Effective for RLS in Japanese Patients
July 10, 2006
- Combined Income-Outlay Reform Proposal Calls for Review of Range of Health Insurance Benefits
July 3, 2006
- MEDICAL DEVICE NEWS IN BRIEF
July 3, 2006
- Industry Prepared to Pay More Feesto Increase Number of Reviewers: Dr Aoki
July 3, 2006
- REPORT
July 3, 2006
- Korosho Has Budget to Conduct Market Price Survey This Year: HIB Official
July 3, 2006
- TOPICS 2 articles
July 3, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…